INT50337

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1995
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 24
Total Number 27
Disease Relevance 11.12
Pain Relevance 6.48

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Foxm1) embryo development (Foxm1) DNA binding (Foxm1)
transcription factor binding (Foxm1) cytoplasm (Foxm1)
Anatomy Link Frequency
ear 2
endocrine cells 1
brain 1
striatum 1
neural 1
Foxm1 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 374 99.80 Very High Very High Very High
antagonist 99 99.76 Very High Very High Very High
agonist 118 99.68 Very High Very High Very High
Cannabinoid receptor 81 99.68 Very High Very High Very High
Cannabinoid 241 99.28 Very High Very High Very High
guanethidine 1 98.34 Very High Very High Very High
Intracerebroventricular 3 95.84 Very High Very High Very High
depression 12 94.40 High High
rheumatoid arthritis 65 88.76 High High
tolerance 21 85.32 High High
Disease Link Frequency Relevance Heat
Lung Cancer 372 100.00 Very High Very High Very High
INFLAMMATION 341 99.80 Very High Very High Very High
Cancer 296 99.80 Very High Very High Very High
Apoptosis 71 99.60 Very High Very High Very High
Urological Neuroanatomy 35 98.06 Very High Very High Very High
Targeted Disruption 59 98.04 Very High Very High Very High
Depression 12 94.40 High High
Primary Sclerosing Cholangitis 88 94.16 High High
Hyperglycemia 14 90.64 High High
Contact Dermatitis 87 89.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
FoxM1 is highly expressed within pancreatic endocrine cells during embryogenesis and is downregulated with age (9), corresponding with reduced ?
Negative_regulation (downregulated) of FoxM1 in endocrine cells
1) Confidence 0.43 Published 2008 Journal Diabetes Section Body Doc Link PMC2570403 Disease Relevance 0.41 Pain Relevance 0.04
The actions of WIN-2 were reversed by the selective cannabinoid CB(1) receptor antagonist [N-piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride] (SR141716A).
Negative_regulation (reversed) of WIN-2 associated with antagonist and cannabinoid
2) Confidence 0.42 Published 2001 Journal Eur. J. Pharmacol. Section Abstract Doc Link 11165232 Disease Relevance 0 Pain Relevance 0.29
The ANOVA test indicates that reduction of ear thickness in the MPM group was statistically different of those from water group (p < 0.07) for the entire experiment.
Negative_regulation (reduction) of MPM in ear
3) Confidence 0.42 Published 2007 Journal J Inflamm (Lond) Section Body Doc Link PMC1845142 Disease Relevance 0.49 Pain Relevance 0.14
These data suggest that another pathway(s), which may mimic that utilized during embryonic pancreas development, compensates for loss of FoxM1 during regeneration, as FoxM1 was also not required for embryonic ?
Negative_regulation (loss) of FoxM1 in pancreas
4) Confidence 0.37 Published 2008 Journal Diabetes Section Body Doc Link PMC2570403 Disease Relevance 0.35 Pain Relevance 0
-cell mass within the splenic lobe was specifically impaired in FoxM1?
Negative_regulation (impaired) of FoxM1 in lobe
5) Confidence 0.37 Published 2008 Journal Diabetes Section Body Doc Link PMC2570403 Disease Relevance 0.17 Pain Relevance 0
-Cell neogenesis following 60% PPx was not impaired in FoxM1?
Negative_regulation (impaired) of FoxM1
6) Confidence 0.37 Published 2008 Journal Diabetes Section Body Doc Link PMC2570403 Disease Relevance 0 Pain Relevance 0
In contrast, acinar and ductal cell proliferation was not impaired in FoxM1?
Negative_regulation (impaired) of FoxM1
7) Confidence 0.37 Published 2008 Journal Diabetes Section Body Doc Link PMC2570403 Disease Relevance 0.07 Pain Relevance 0
Furthermore, we present evidence that loss of FoxM1 did not impair islet neogenesis but did impair islet growth after PPx.
Negative_regulation (loss) of FoxM1
8) Confidence 0.37 Published 2008 Journal Diabetes Section Body Doc Link PMC2570403 Disease Relevance 0.26 Pain Relevance 0
-cell mass following PPx were specifically impaired in FoxM1?
Negative_regulation (impaired) of FoxM1
9) Confidence 0.37 Published 2008 Journal Diabetes Section Body Doc Link PMC2570403 Disease Relevance 0.22 Pain Relevance 0
We can hypothesize that, when SR is administered jointly with WIN, the antagonist blocks the CB1 receptor and in that way inhibits WIN action, while at the same time decreasing the cannabinoid tone and indirectly increasing the rewarding action of MDMA.
Negative_regulation (administered) of WIN associated with cannabinoid and antagonist
10) Confidence 0.32 Published 2010 Journal Behav Brain Funct Section Body Doc Link PMC2858089 Disease Relevance 0.14 Pain Relevance 0.77
We can hypothesize that, when SR is administered jointly with WIN, the antagonist blocks the CB1 receptor and in that way inhibits WIN action, while at the same time decreasing the cannabinoid tone and indirectly increasing the rewarding action of MDMA.
Negative_regulation (inhibits) of WIN associated with cannabinoid and antagonist
11) Confidence 0.32 Published 2010 Journal Behav Brain Funct Section Body Doc Link PMC2858089 Disease Relevance 0.14 Pain Relevance 0.73
The CB1 receptor is not involved in the potentiating effect of WIN.
Negative_regulation (effect) of WIN
12) Confidence 0.32 Published 2010 Journal Behav Brain Funct Section Body Doc Link PMC2858089 Disease Relevance 0 Pain Relevance 0.34
The MPO results showed that the neutrophil infiltration in ear of mice that received hydrocortisone and MPM is reduced compared to the mice receiving water.
Negative_regulation (reduced) of MPM in neutrophil associated with urological neuroanatomy
13) Confidence 0.30 Published 2007 Journal J Inflamm (Lond) Section Body Doc Link PMC1845142 Disease Relevance 0.93 Pain Relevance 0.17
MPM and hydrocortisone administered p.o. either in a prophylactic (Figure 1B) or a therapeutic fashion (Figure 1C) reduced the inflammation with similar efficiency as demonstrated by the reduction of ear redness and thickness.
Negative_regulation (reduced) of MPM in ear associated with inflammation
14) Confidence 0.30 Published 2007 Journal J Inflamm (Lond) Section Body Doc Link PMC1845142 Disease Relevance 1.19 Pain Relevance 0.56
Spiroperidol (a D2 receptor blocker), (+)-SCH 23390 (a D1 receptor blocker), or prior 6-OHDA lesions of the striatum blocked Win 55212-2- and CP 55940-induced turning, thus suggesting the involvement of DA transmission in cannabinoid-induced turning.
Negative_regulation (blocked) of Win in striatum associated with cannabinoid
15) Confidence 0.30 Published 1995 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 7617730 Disease Relevance 0 Pain Relevance 0.38
PS-341 (bortezomib) is a newly developed proteasome inhibitor which induced apoptosis in cancer cells by inhibiting the activity of the Forkhead BoxM1 (FoxM1) transcription factor [140].
Negative_regulation (inhibiting) of Forkhead BoxM1 associated with cancer and apoptosis
16) Confidence 0.23 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2842969 Disease Relevance 1.11 Pain Relevance 0.14
When NANC relaxant neural responses (presence of atropine (10(-6) M) and guanethidine (10(-6) M)) were induced by EFS, the cannabinoid receptor agonists anandamide and Win 55,212-2 reduced the relaxant response, an effect that could be reversed by the cannabinoid receptor antagonist AM 630 for anandamide, but not for Win 55,212-2.
Neg (not) Negative_regulation (reversed) of Win in neural associated with cannabinoid receptor, guanethidine, antagonist and agonist
17) Confidence 0.13 Published 2002 Journal Can. J. Physiol. Pharmacol. Section Abstract Doc Link 11911227 Disease Relevance 0 Pain Relevance 0.83
SR 141716 (0.32 microM) markedly attenuated the WIN 55,212-2-induced inhibition in guinea-pig and human brain slices.
Negative_regulation (inhibition) of WIN in brain
18) Confidence 0.10 Published 1997 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 9402037 Disease Relevance 0 Pain Relevance 0.20
Since TUSC2 is commonly suppressed in MPM (see above) we used forced expression of TUSC2 to identify its targets.
Negative_regulation (suppressed) of MPM associated with lung cancer
19) Confidence 0.03 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2776015 Disease Relevance 0.52 Pain Relevance 0
The cannabinoid CB1 receptor antagonist, SR141716A (0.1-100 nM), but not the cannabinoid CB2 receptor antagonist, SR144528 (0.1-100 nM), reduced in a dose-related manner WIN 55,212-2-and cannabinol-induced inhibition of nitrite production.
Negative_regulation (inhibition) of WIN associated with antagonist and cannabinoid
20) Confidence 0.03 Published 2001 Journal J. Neurochem. Section Abstract Doc Link 11520904 Disease Relevance 0.14 Pain Relevance 0.42

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox